Frontiers in Hematology

Clinical Trial

Published on 22 Apr 2025

Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations

in Blood Cancer

Bhavana Bhatnagar
Daelynn R. Buelow
Kaitlyn M. Dvorak-Kornaus
Shelley J. Orwick
Jae Yoon Jeon
Zahra Talebi
Amy S. Ruppert
James S. Blachly
Uma Borate
Sharyn D. Baker

Frontiers in Hematology

doi 10.3389/frhem.2025.1554764

1,819 views

Review

Published on 21 Mar 2025

Exercise and diet studies among patients living with multiple myeloma: current evidence and considerations of patient preferences

in Blood Cancer

Kelsey E. Maslana
Grace E. Skogerboe
Douglas W. Sborov
Adriana M. Coletta

Frontiers in Hematology

doi 10.3389/frhem.2025.1550681

3,560 views

Case Report

Published on 04 Mar 2025

Case Report: Triplet combination with pirtobrutinib/venetoclax/rituximab in accelerated phase of chronic lymphocytic leukemia

in Blood Cancer

Andrea Serafin
Alessandro Cellini
Francesco Angotzi
Valeria Ruocco
Arianna Bevilacqua
Marco Pizzi
Livio Trentin
Andrea Visentin

Frontiers in Hematology

doi 10.3389/frhem.2025.1552200

1,723 views

Review

Published on 03 Mar 2025

Abnormalities of primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, the coagulation system, and the bone marrow microenvironment

in Blood Cancer

Jahan Abdi
Payman Nasr

Frontiers in Hematology

doi 10.3389/frhem.2025.1435193

2,502 views
1 citation

Case Report

Published on 26 Feb 2025

Acquired von Willebrand disease associated with smoldering multiple myeloma and hereditary hemorrhagic telangiectasia successfully treated with daratumumab, pomalidomide, and dexamethasone: hitting three birds with one stone? – case report

in Blood Cancer

Lemchukwu Amaeshi
Jacqueline N. Poston
Mansour Gergi

Frontiers in Hematology

doi 10.3389/frhem.2025.1499500

1,886 views

Original Research

Published on 21 Feb 2025

Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events

in Blood Cancer

Amman Bhasin
Adam Finn Binder
Leland Damron
Amry Majeed
Adam Barsouk
Kelly Hughes
Niketa Raj
Abdullateef O. Abdulkareem
Tingting Zhan
Divya Polu

Frontiers in Hematology

doi 10.3389/frhem.2025.1521017

1,244 views

Original Research

Published on 21 Jan 2025

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study

in Blood Cancer

Sam Salek
Samantha Nier
Zack Pemberton-Whiteley
Tatyana Ionova
Giuseppe Ianni
Giovanni Tripepi
Nick York
Nicole Schroeter
Kathryn Huntley
Michael Rynne

Frontiers in Hematology

doi 10.3389/frhem.2024.1502166

4,294 views
2 citations

Case Report

Published on 16 Jan 2025

Case report: VEXAS syndrome: first documented cases in Latin America

in Blood Cancer

Carolina Ottati
Inés Gervaz
Martín Yandian
Matilde Boada
Gabriela Vidal-Senmache
Percy Ortiz-Guerra
Ana I. Catalán
Patricia Kutscher
Diego Lopez
Lilian Diaz

Frontiers in Hematology

doi 10.3389/frhem.2024.1501337

1,570 views

Case Report

Published on 10 Jan 2025

Case report: A decade-long journey with cyclic thrombocytopenia

in Blood Cancer

Talal Al-Assil
Suhaib Ellythy
Omer A. Idris
Mohammad Omaira

Frontiers in Hematology

doi 10.3389/frhem.2024.1482891

1,785 views

Mini Review

Published on 24 Dec 2024

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

in Blood Cancer

Joshua W. Bliss
Spencer Krichevsky
Joseph Scandura
Ghaith Abu-Zeinah

Frontiers in Hematology

doi 10.3389/frhem.2024.1504327

1,861 views

Case Report

Published on 17 Dec 2024

A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report

in Blood Cancer

Monika A. Satoskar
Matthew R. Lordo
Daniel M. Jones
Nicholas B. Nowacki
Jonathan E. Brammer
John C. Reneau
Timothy J. Voorhees

Frontiers in Hematology

doi 10.3389/frhem.2024.1463487

1,510 views

Case Report

Published on 12 Dec 2024

Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report

in Blood Cancer

Selene Grano
Valentina Bonuomo
Diana Carli
Veronica Peri
Loredana Farinasso
Ugo Ramenghi
Daniela Cilloni
Carmen Fava

Frontiers in Hematology

doi 10.3389/frhem.2024.1508463

1,267 views

Study Protocol

Published on 06 Dec 2024

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

in Blood Cancer

Theo Leitner
Evgenii Shumilov
Christina Schwitlick
Raphael Koch
Franziska Hamm
Marion Högner
Florian Bassermann
Katja Weisel
Hermann Einsele
Martin Kortüm

Frontiers in Hematology

doi 10.3389/frhem.2024.1436845

2,131 views

Original Research

Published on 05 Dec 2024

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

in Blood Cancer

Manuel Neves
Rita Gerivaz
Graça Esteves
Rui Bergantim
Gisela Ferreira
Henrique Coelho
Celina Afonso
Delfim Duarte
Anabela Neves
Helena Matos Silva

Frontiers in Hematology

doi 10.3389/frhem.2024.1480120

1,720 views

Original Research

Published on 22 Nov 2024

Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia

in Blood Cancer

Somedeb Ball
Najla H. Al Ali
Akriti G. Jain
Luis E. Aguirre
Seongseok Yun
Onyee Chan
Zhuoer Xie
David A. Sallman
Jeffrey Lancet
Eric Padron

Frontiers in Hematology

doi 10.3389/frhem.2024.1492680

1,280 views

Case Report

Published on 13 Nov 2024

Case report: VEXAS syndrome and literature review

in Blood Cancer

Can Jones
Stanislav Ivanov
Pablo Ferraro
Souhad Younes
Hugo Fernandez

Frontiers in Hematology

doi 10.3389/frhem.2024.1480436

2,136 views
2 citations

Review

Published on 29 Oct 2024

Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring

in Blood Cancer

Binsah George
Kok Hoe Chan
Adan Rios

Frontiers in Hematology

doi 10.3389/frhem.2024.1463410

8,141 views
2 citations

Perspective

Published on 18 Oct 2024

The CHIP-clinic as the catalyst of preventive medicine

in Blood Cancer

Hans Carl Hasselbalch
Vibe Skov
Lasse Kjaer
Trine Alma Knudsen
Christina Schjellerup Eickhardt-Dalbøge
Christina Ellervik
Sabrina Cordua
Anders Lindholm Sørensen
Sarah Friis Christensen
Marie Hvelplund Kristiansen

Frontiers in Hematology

doi 10.3389/frhem.2024.1459154

2,647 views
2 citations

Review

Published on 07 Oct 2024

Clonal evolution: a landmark of MPN evolution

in Blood Cancer

Nabih Maslah
Stephane Giraudier
Bruno Cassinat
Jean-Jacques Kiladjian

Frontiers in Hematology

doi 10.3389/frhem.2024.1473920

2,423 views

Original Research

Published on 11 Sep 2024

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation

in Blood Cancer

Amalia Domingo-González
Rafael Alonso Fernández
Ana Jiménez
Teresa De Soto Álvarez
Ana Lerma-Verdejo
Virginia Pradillo
Gonzalo Benzo Callejo
Jose Sánchez-Pina
Elena Landete
Alberto Velasco-Valdazo

Frontiers in Hematology

doi 10.3389/frhem.2024.1438233

1,511 views

Editorial

Published on 14 Aug 2024

Editorial: Glycobiology in hematology: a promising avenue for cancer diagnostics and therapeutics

in Blood Cancer

Tao Zhang
Valerie R. Wiersma

Frontiers in Hematology

doi 10.3389/frhem.2024.1465473

1,379 views

Community Case Study

Published on 25 Jul 2024

Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study

in Blood Cancer

Barbara Loteta
Annalisa Pitino
Martina Pitea
Caterina Alati
Giovanni Tripepi
Maria Caterina Mico'
Maria Pellicano'
Francesca Cogliandro
Gaetana Porto
Giorgia Policastro

Frontiers in Hematology

doi 10.3389/frhem.2024.1441070

1,375 views

Mini Review

Published on 22 Jul 2024

Targeting the bone marrow niche, moving towards leukemia eradication

in Blood Cancer

Carla Semedo
Raquel Caroço
António Almeida
Bruno António Cardoso

Frontiers in Hematology

doi 10.3389/frhem.2024.1429916

3,117 views
1 citation

Review

Published on 12 Jul 2024

Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets

in Blood Cancer

Cristian C. Taborda
Amer M. Zeidan
Lourdes M. Mendez

Frontiers in Hematology

doi 10.3389/frhem.2024.1419323

6,546 views
3 citations

79 articles

articles

Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations

Exercise and diet studies among patients living with multiple myeloma: current evidence and considerations of patient preferences

Case Report: Triplet combination with pirtobrutinib/venetoclax/rituximab in accelerated phase of chronic lymphocytic leukemia

Abnormalities of primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, the coagulation system, and the bone marrow microenvironment

Acquired von Willebrand disease associated with smoldering multiple myeloma and hereditary hemorrhagic telangiectasia successfully treated with daratumumab, pomalidomide, and dexamethasone: hitting three birds with one stone? – case report

Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study

Case report: VEXAS syndrome: first documented cases in Latin America

Case report: A decade-long journey with cyclic thrombocytopenia

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report

Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia

Case report: VEXAS syndrome and literature review

Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring

The CHIP-clinic as the catalyst of preventive medicine

Clonal evolution: a landmark of MPN evolution

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation

Editorial: Glycobiology in hematology: a promising avenue for cancer diagnostics and therapeutics

Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study

Targeting the bone marrow niche, moving towards leukemia eradication

Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets